Electronic Patch to Improve Chronic Wound Monitoring Announced by Graphene Flagship

February 5, 2020

Electronic Patch: Graphene Flagship associated member, Grapheal has developed a pioneering wearable patch for the remote monitoring of chronic wounds.

The flexible and transparent graphene-based biosensor enables doctors and nurses to provide hyper-responsive treatment of chronic wounds. The device will be showcased at Deep Tech EU, at Mobile World Congress 2020, held in Barcelona, Spain on February 24 to 27, 2020.

Evidence suggests effective wound care will become critical for healthcare in Europe as the population ages and the prevalence of chronic wounds increases. The growing frequency of diabetes in Europe is exacerbating the situation, with approximately 5.5 percent of 60 million diabetics in Europe developing a foot wound.

Chronic wounds can take months or even years to heal. In 20 percent of the cases, the injury never heals and can lead to limb amputation. This dramatic consequence is on the rise, with a 19.4 percent increase in limb amputations during 2014-2017 compared to 2010-2013.

At Deep Tech EU, the largest showcase of technologies born out of European Flagships, Grapheal, a spin-off from CNRS-Grenoble (France) will demonstrate how its wound monitoring technology will change the way the healthcare industry deals with the chronic wound epidemic.

Connected to a smartphone, Grapheal’s wearable patch enables continuous monitoring of wounds, to empower caregivers and wound sufferers with a smart and accurate assessment tool. The wound patch measures and stores the bio parameters of the wound and communicates this data to the cloud via a smartphone app. This real-time connectivity ensures nurses and doctors can be alerted to early stages of infection and other complications.

“Our patented formula uses Graphene-on-polymer, in a non-invasive way, to actively react to any changes to the wound”, explained Vincent Bouchiat, Grapheal CEO. “As an atomically thin material, graphene’s electrode conductivity will change according to any physicochemical change, enabling faster detection of problems for patients.”

“Our patch can adapt to any shape of the wound, using Graphene’s thin and flexible properties. In fact, the non-invasive nature of the patch actively stimulates wound healing — and we have led eight preclinical studies to prove its biostimulation properties.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”